VUSE Premarket Tobacco Product Application filed for substantive review by the FDA
27 November 2019
British American Tobacco’s U.S. subsidiary Reynolds American Inc. (RAI) has today announced that the recently-submitted Premarket Tobacco Product Application (PMTA) for VUSE vapour products has been filed by the Food and Drug Administration (FDA) for substantive scientific review, moving the application one step further through the review process.
“This is a first-of-its-kind application for VUSE products, and it puts VUSE one step closer to gaining a marketing order from the FDA”, says RAI CEO Ricardo Oberlander.
“The FDA will now review our scientific justification and determine the appropriateness of VUSE e-cigarette products against the public health standard.
“For adult tobacco consumers seeking an alternative source of nicotine, having FDA oversight of e-cigarette products is an important step to ensure those alternatives meet strict regulatory scrutiny.”
The FDA’s scientific review of the VUSE application – which totals more than 150,000 pages of research and data – comes just over six weeks after its initial submission to the FDA. The FDA, per its earlier-issued guidance, considers the following issues, among others:
Dr. James Figlar, Executive Vice President within the RAI Group, explained the science behind the application, stating that: "We compiled both the data and clinical information necessary for predicting the effect of continued marketing of VUSE products on the public health. We surveyed current tobacco users to understand product use behaviour and demographics, conducted behavioural studies of current and non-users of tobacco to gauge consumer understanding of risks and interest in product use, and performed statistical population modelling to project the effect on the population as a whole.”
He continued: “We also conducted clinical studies that looked at the abuse potential of VUSE products, which included examining nicotine pharmacokinetics, as well as conducted several studies to examine the aerosol properties of the products and the temperature during use.
“While many of the results of our studies are confidential and proprietary, we believe that our application is complete and meets the regulatory requirements laid out in FDA’s guidance, and we will work with the Agency to address any questions they may have about our products throughout the review process.”
The next step in the review process is the FDA evaluation of the scientific information and data in the VUSE application. The FDA will also conduct inspections of manufacturing sites, as well as sites and entities involved in clinical and nonclinical studies, as part of this review process. Thereafter, the application may receive market clearance or denial, based on the FDA’s evaluation of the application and evidence.
Reynolds American Inc. is an indirect, wholly-owned subsidiary of British American Tobacco p.l.c., and the U.S. parent company of R. J. Reynolds Tobacco Company; Santa Fe Natural Tobacco Company, Inc.; American Snuff Company, LLC; R. J. Reynolds Vapor Company; and Kentucky BioProcessing, Inc.
To learn more about Reynolds American Inc. and its operating companies, please visit www.reynoldsamerican.com .
This is a release by British American Tobacco p.l.c. References to ‘British American Tobacco’, ‘BAT’, ‘we’, ‘us’ and ‘our’ when denoting opinion refer to British American Tobacco p.l.c. (the Company, and together with its subsidiaries, the “Group”), and when denoting tobacco business activity refer to Group operating companies, collectively or individually as the case may be. This release contains certain forward-looking statements, including those made within the meaning of Section 21E of the United States Securities Exchange Act of 1934, regarding our intentions, beliefs or current expectations reflecting knowledge and information available at the time of preparation and concerning, amongst other things, prospects, growth, strategies, compliance with regulatory guidelines, our ability to submit further regulatory applications, the success of our regulatory applications and the economic and business circumstances occurring from time to time in the countries and markets in which the Group operates. BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.
These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “will,” “estimate,” “strategy” and similar expressions. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated, including uncertainties related to the impact of adverse domestic or international legislation and regulation and adverse decisions by domestic or international regulatory bodies.
Additional information concerning these and other factors can be found in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including the Annual Report on Form 20-F filed on 15 March 2019 and Current Reports on Form 6-K, which may be obtained free of charge at the SEC’s website, http://www.sec.gov, and the Company’s Annual Reports, which may be obtained free of charge from the British American Tobacco website www.bat.com.